EORTC is currently conducting A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with Retroperitoneal sarcomas (RPS) - STRASS. SPAEN has developed a leaflet/article explaining the STRASS study in non-technical terms with the aim to help patients and carers understand what the study might be able to offer them. This summary is not part of the study information and is not intended to replace any of the study information which is part of the informed consent process.
The annual British Sarcoma Group Conference 2012 - Personalising Treatment and Care took place in Oxfordshire from 29 February - 2 March 2012. It is the main educational and networking event for all UK healthcare professionals and allied healthcare professionals treating patients with sarcoma. It was attended by almost 200 delegates representing a wide range of disciplines including oncology, surgery, pathology, research, specialist nursing, and physiotherapy, alongside representatives from the pharmaceutical industry, patient organisations and charities.
Sarcomas are rare malignant tumors, with an overall incidence of 6/105/year. Bone and soft tissue connective tissue tumours encompass more than 50 different rare histotypes and more than 150 different molecular subtypes. The incidence of individual rare sarcomas subtypes is often less than 0.5/105/year. Given the rarity of sarcomas as a group, but even more as individual entities, few prospective clinical trials testing local or systemic treatments have been performed in specific subtypes of sarcomas. Clinical trials in specific histological and molecular subtypes of sarcoma can only be performed through integrated clinical networks, centres of clinical excellence, supported by translational analysis.
The campaign Rare Cancers Europe has been developed by ESMO in collaboration with major European stakeholders in rare cancers and rare diseases to address challenges and propose solutions to eliminate the hurdles that patients with rare cancers, researchers, medical professionals and the pharmaceutical industry working in this field face every day. Rare Cancers Europe (RCE) has been established as a partnership of cooperating organisations that work together to place the issue of rare cancers firmly on the European policy agenda, to identify and promote appropriate solutions and to exchange best practice. SPAEN has now been welcomed into the partnership initiative. http://www.rarecancerseurope.org
SPAEN regrets the released information from AB Science: “Masitinib significantly extends overall survival as second-line drug for GIST…”
On the 1st of February 2012 the “Global GIST Community” was confronted by a press release from a pharmaceutical company named AB Science to the financial media and a supporting Email “Late Breaking News” from the Life Raft Group (NJ, USA) to the GIST Patient Community. During the following days, leading GIST Experts and GIST Patient Groups around the world clearly expressed their concern about the content of this press release and manner of its delivery.
Review paper "The Combination of Surgery and Imatinib in GIST: A Reality for Localized Tumors at High Risk, an Open Issue for Metastatic Ones"
The Liddy Shriver Sarcoma Initiative publishes accurate and timely information about the diagnosis and treatment of sarcomas in ESUN, its online, peer-reviewed newsletter. Recently they have published the ESUN Guide for the Newly Diagnosed. The ESUN Sarcoma Guides have been reviewed by sarcoma experts and published as eBooks for easy access on-the-go. The books can be saved and printed for individual use.
2nd SPAEN Conference 2011 held at 17. – 19. November 2011 in Berlin (Germany)
Nearly 100 participants who attended the 2nd SPAEN Annual Conference for organizations representing patients with Sarcomas incl. GIST or Desmoid-Tumours held in Berlin, documented the increasing interest in the disease group of Sarcomas, which is in many European countries a ‘forgotten cancer’, because it is one of the rarest forms of cancer. Among the participants were more than 55 representatives from Sarcoma Patient Advocacy Groups from 14 countries, several European Sarcoma Experts and industry representatives. The meeting focused on research and treatment for Sarcomas and advocacy/capacity building for Sarcoma Patient Groups. The main aims of the conference were supporting patient advocates to develop new knowledge and skills about the diagnosis and treatment of Sarcomas and discussing and sharing best practice to enhance their daily work as patient advocates.